Thermo Fisher Scientific completed the acquisition of Henogen from Novasep for $879m.

Thermo Fisher Scientific, a provisioner of scientific instrumentation, completed the acquisition of Henogen, a biomanufacturing company, from Novasep, a healthcare services company, for $879m. "Novasep's viral vector business is an excellent strategic fit as Thermo Fisher continues to expand its capabilities for cell and gene vaccines and therapies globally. The addition of their manufacturing capabilities in Europe complements our four development and manufacturing sites in North America. In addition, they bring an incredibly talented team with more than two decades of experience across a broad range of viral vectors. The combination will benefit our global customers seeking support and capacity in the region as well as European customers bringing new medicines to patients inside and outside of Europe," Michel Lagarde, Thermo Fisher President.